Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008

Tuesday, October 28, 2008 General News J E 4
NANJING, China, Oct. 27 Simcere PharmaceuticalGroup (NYSE: SCR), a leading manufacturer and supplier of branded genericpharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidlygrowing China market, announced today its participation in the Goldman SachsChina Investment Frontier Conference 2008. The conference will be held at theGrand Hyatt Beijing hotel on November 3-4, 2008.

Simcere's chief executive officer, Jinsheng Ren, chief financial officer,Frank Zhigang Zhao, and vice president of marketing, Mark Chen, will attendthe conference on Thursday November 4. Jinsheng Ren will speak at the Track IPanel session headlined Healthcare: Reform of the Healthcare System: Impactand Likely Winners, which will take place on November 4, between 08:00-09:00Beijing time. Later that afternoon, Frank Zhigang Zhao will give a companypresentation to investors between 16:30-17:30.

A copy of Simcere's investor presentation will be available on theinvestor relations portion of the Company's Web site, located at .

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer andsupplier of branded generic and innovative anti-cancer pharmaceuticals in therapidly growing China market. In recent years, Simcere Pharmaceutical Grouphas focused its strategy on the development of first-to-market generic andinnovative pharmaceuticals, and has introduced a first-to-market generic anti-stroke medication under the brand name Bicun and an innovative anti-cancermedication under the brand name Endu. It currently manufactures and sells 39principal pharmaceutical products including antibiotics, anti-cancermedication and anti-stroke medication and is the exclusive distributor ofthree additional pharmaceuticals that are marketed under its brand names.Simcere concentrates its research and development efforts on the treatment ofdiseases with high incidence and/or mortality rates and for which there is aclear demand for more effective pharmacotherapy such as cancer, strokes,osteoporosis and infectious diseases. For more information about SimcerePharmaceutical Group, please visit .For investor and media inquiries, please contact: In Nanjing: Frank Zhigang Zhao Chief Financial Officer Simcere Pharmaceutical Group Tel: +86-25-8556-6666 ext. 8818 Email: In Beijing: Kejia Wu Brunswick Group Tel: +86-10-6566-4651 In Hong Kong: Joseph Lo Chi-Lun Brunswick Group Tel: +852-3512-5033 In New York: Michael Guerin Brunswick Group LLC Tel: +1-212-333-3810

SOURCE Simcere Pharmaceutical Group


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Research Shows Consumer-Directed Health Plans Enco...
Baptist Health System Deploys Sentillion's Vergenc...